Welcome to our dedicated page for GERRESHEIMER AFR news (Ticker: GRRMY), a resource for investors and traders seeking the latest updates and insights on GERRESHEIMER AFR stock.
Gerresheimer is an innovative provider of systems and solutions for the pharma, biotech, and cosmetic industries, offering a wide range of pharmaceutical containment solutions, drug delivery systems, medical devices, and digital solutions for therapy support. With a global presence and over 11,000 employees, the company generated revenues of approximately €1.82bn in 2022.
Gerresheimer AG reported a strong start to 2021, achieving revenues of EUR 303 million in Q1, a 3.1% increase year-on-year. Growth was driven by the Plastics & Devices Division, with a notable demand for syringes and pharmaceutical packaging. Adjusted EBITDA rose to EUR 54 million, reflecting a 29.3% year-on-year increase in adjusted earnings per share at EUR 0.57. The company forecasts mid single-digit revenue growth for 2021 and aims for an adjusted EBITDA margin of 22-23%. Gerresheimer is expanding production for Covid-19 vaccine vials, reinforcing its role in the pandemic response.
FAQ
What is the market cap of GERRESHEIMER AFR (GRRMY)?
What does Gerresheimer do?
How many employees does Gerresheimer have?
Where is Gerresheimer headquartered?
What is Gerresheimer's revenue in 2022?
In which stock exchange is Gerresheimer listed?
What is the status of Gerresheimer's sustainability performance?
How many production sites does Gerresheimer have?
What products does Gerresheimer offer?
What are Gerresheimer's sustainability targets?
What external sustainability ratings does Gerresheimer have?